Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Comparison of Real-time Quantitative Polymerase Chain Reaction and Eight-color Flow Cytometry in Assessment of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F18%3A00069034" target="_blank" >RIV/65269705:_____/18:00069034 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/60162694:G44__/18:43889628 RIV/00216224:14110/18:00101862 RIV/00216208:11110/18:10382061 RIV/00216208:11150/18:10382061 a 2 dalších

  • Výsledek na webu

    <a href="https://www.sciencedirect.com/science/article/pii/S2152265018305615" target="_blank" >https://www.sciencedirect.com/science/article/pii/S2152265018305615</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.clml.2018.06.030" target="_blank" >10.1016/j.clml.2018.06.030</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Comparison of Real-time Quantitative Polymerase Chain Reaction and Eight-color Flow Cytometry in Assessment of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia

  • Popis výsledku v původním jazyce

    We evaluated the usefulness of flow cytometry (FCM) and real-time quantitative polymerase chain reaction (PCR) in the assessment of minimal residual disease (MRD) in adult acute lymphoblastic leukemia. The analysis showed that both FCM and real-time quantitative PCR MRD methods are sensitive for survival prediction during induction. However, FCM was not sufficiently sensitive in later phases of treatment. Background: Minimal residual disease (MRD) is an important prognostic maker in acute lymphoblastic leukemia (ALL). However, few data comparing the measurement of adult ALL MRD using different methods in daily practice are available. We conducted an analysis comparing the importance of flow cytometry (FCM) and real-time quantitative polymerase chain reaction (PCR) in the assessment of MRD in adult ALL. Patients and Methods: Fifty-six consecutive adult patients with both Philadelphia-negative and -positive ALL treated according to an intensive protocol were enrolled in the study. Bone marrow samples were acquired on day 26 and during week 11 of treatment. MRD evaluation was performed using 8-color FCM and PCR of immunoglobulin or T-cell receptor gene clonal rearrangements and BCR-ABL1, KMT2A-AF4 and E2A-PBX1 fusion genes. Results: On day 26, both FCM and PCR seemed to have good discrimination sensitivity for overall survival (P =.001 to.008) and progression-free survival (P =.03 to.04) prediction for both Philadelphia-positive and -negative cases. The most sensitive method in week 11 was PCR including all results &gt; 0 considered to indicate MRD positivity (P =.002 for overall survival and P =.02 for progression-free survival). PCR with other cutoffs was not sufficiently sensitive in week 11. Moreover, no FCM thorn samples were found in week 11. The subanalysis of the Philadelphia-negative patients showed similar results. Conclusion: Our analysis showed that both FCM and PCR MRD assessment methods are sensitive for survival prediction during induction. However, we believe FCM could not be sufficiently sensitive in later phases of treatment. (C) 2018 Elsevier Inc. All rights reserved.

  • Název v anglickém jazyce

    Comparison of Real-time Quantitative Polymerase Chain Reaction and Eight-color Flow Cytometry in Assessment of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia

  • Popis výsledku anglicky

    We evaluated the usefulness of flow cytometry (FCM) and real-time quantitative polymerase chain reaction (PCR) in the assessment of minimal residual disease (MRD) in adult acute lymphoblastic leukemia. The analysis showed that both FCM and real-time quantitative PCR MRD methods are sensitive for survival prediction during induction. However, FCM was not sufficiently sensitive in later phases of treatment. Background: Minimal residual disease (MRD) is an important prognostic maker in acute lymphoblastic leukemia (ALL). However, few data comparing the measurement of adult ALL MRD using different methods in daily practice are available. We conducted an analysis comparing the importance of flow cytometry (FCM) and real-time quantitative polymerase chain reaction (PCR) in the assessment of MRD in adult ALL. Patients and Methods: Fifty-six consecutive adult patients with both Philadelphia-negative and -positive ALL treated according to an intensive protocol were enrolled in the study. Bone marrow samples were acquired on day 26 and during week 11 of treatment. MRD evaluation was performed using 8-color FCM and PCR of immunoglobulin or T-cell receptor gene clonal rearrangements and BCR-ABL1, KMT2A-AF4 and E2A-PBX1 fusion genes. Results: On day 26, both FCM and PCR seemed to have good discrimination sensitivity for overall survival (P =.001 to.008) and progression-free survival (P =.03 to.04) prediction for both Philadelphia-positive and -negative cases. The most sensitive method in week 11 was PCR including all results &gt; 0 considered to indicate MRD positivity (P =.002 for overall survival and P =.02 for progression-free survival). PCR with other cutoffs was not sufficiently sensitive in week 11. Moreover, no FCM thorn samples were found in week 11. The subanalysis of the Philadelphia-negative patients showed similar results. Conclusion: Our analysis showed that both FCM and PCR MRD assessment methods are sensitive for survival prediction during induction. However, we believe FCM could not be sufficiently sensitive in later phases of treatment. (C) 2018 Elsevier Inc. All rights reserved.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30204 - Oncology

Návaznosti výsledku

  • Projekt

    Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

  • Návaznosti

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Ostatní

  • Rok uplatnění

    2018

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Clinical Lymphoma Myeloma &amp; Leukemia

  • ISSN

    2152-2650

  • e-ISSN

  • Svazek periodika

    18

  • Číslo periodika v rámci svazku

    11

  • Stát vydavatele periodika

    US - Spojené státy americké

  • Počet stran výsledku

    6

  • Strana od-do

    743-748

  • Kód UT WoS článku

    000448263400013

  • EID výsledku v databázi Scopus

    2-s2.0-85050389697